In releasing its annual report Monday on the health of Medicare's two trust funds, the U.S. Medicare Board of Trustees noted that Part D prescription drug spending projections were "lower than in last year's report because of slower price growth and a continuing trend of higher manufacturer rebates," according to the Centers for Medicare & Medicaid Services.